GeoVax Labs, Inc. Share Price & Technical Analysis
GOVX · $2.01 (-4.29%)
Healthcare / Biotechnology
$2.01
-4.29%
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of so…
Price chart
Seasonality
Jun has 1 positive and 4 negative years (last 5 years shown)
-9% return in Jun, 14% avg return in past 3 year Jun month.
-31% return in 2026, -72% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -36% | -43% | -12% | -21% | 91% | -9% | – | – | – | – | – | – | -31% |
| 25 | -25% | -23% | -36% | -8% | -1% | -18% | 27% | 4% | -36% | 13% | -27% | -58% | -188% |
| 24 | -41% | -24% | -22% | -30% | 25% | 70% | -36% | 115% | -47% | -18% | 32% | -8% | 17% |
| 23 | 28% | -17% | -6% | -5% | 2% | -10% | 5% | 1% | -10% | -5% | -13% | -16% | -46% |
| 22 | -35% | -28% | -37% | -31% | 126% | -53% | 228% | -72% | -4% | -18% | -16% | -18% | 42% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Uptrend
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$10.89M
P/E ratio
—
52W high
$34.75
52W low
$0.96
Volume
5,06,400
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is GeoVax Labs, Inc. share price today?
- GeoVax Labs, Inc. (GOVX) last traded around $2.01 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does GOVX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GOVX. Download the app for real-time alerts.
- How can I analyze GeoVax Labs, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.